AU2007291891B2 - Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions - Google Patents

Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions Download PDF

Info

Publication number
AU2007291891B2
AU2007291891B2 AU2007291891A AU2007291891A AU2007291891B2 AU 2007291891 B2 AU2007291891 B2 AU 2007291891B2 AU 2007291891 A AU2007291891 A AU 2007291891A AU 2007291891 A AU2007291891 A AU 2007291891A AU 2007291891 B2 AU2007291891 B2 AU 2007291891B2
Authority
AU
Australia
Prior art keywords
antibody
ephb4
cancer
egg product
containing milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007291891A
Other languages
English (en)
Other versions
AU2007291891A1 (en
Inventor
Antony William Scammell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acn 135 493 391 Pty Ltd
Original Assignee
A C N 135 493 391 Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904752A external-priority patent/AU2006904752A0/en
Application filed by A C N 135 493 391 Pty Ltd filed Critical A C N 135 493 391 Pty Ltd
Priority to AU2007291891A priority Critical patent/AU2007291891B2/en
Publication of AU2007291891A1 publication Critical patent/AU2007291891A1/en
Application granted granted Critical
Publication of AU2007291891B2 publication Critical patent/AU2007291891B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/04—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from milk
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2007291891A 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions Ceased AU2007291891B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007291891A AU2007291891B2 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2006904752A AU2006904752A0 (en) 2006-08-31 Uses for Antibodies
AU2006904752 2006-08-31
PCT/AU2007/001282 WO2008025099A1 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions
AU2007291891A AU2007291891B2 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Publications (2)

Publication Number Publication Date
AU2007291891A1 AU2007291891A1 (en) 2008-03-06
AU2007291891B2 true AU2007291891B2 (en) 2013-10-31

Family

ID=39135433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007291891A Ceased AU2007291891B2 (en) 2006-08-31 2007-08-31 Treatment and/or prevention of non-infectious medical conditions using antibody-containing compositions

Country Status (8)

Country Link
US (2) US20100297140A1 (OSRAM)
EP (1) EP2061510B1 (OSRAM)
JP (1) JP2010501596A (OSRAM)
CN (1) CN101626784B (OSRAM)
AU (1) AU2007291891B2 (OSRAM)
DK (1) DK2061510T3 (OSRAM)
NZ (1) NZ575918A (OSRAM)
WO (1) WO2008025099A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2244735A4 (en) 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
EP3461840A1 (en) 2009-04-27 2019-04-03 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of non alcoholic steatohepatitis
JP2011026252A (ja) * 2009-07-27 2011-02-10 Kitasato Institute 上皮成長因子受容体に対する卵黄抗体およびその用途
EP2605791B1 (en) 2010-08-17 2017-03-08 Immuron Limited Anti-lps enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
ES2742734T3 (es) 2010-11-23 2020-02-17 Pantheryx Inc Composiciones y procedimientos para el tratamiento en aplicaciones clínicas de espectro general, no diferenciadas o mixtas
TWI655210B (zh) * 2010-12-08 2019-04-01 艾伯維史坦森特瑞斯有限責任公司 新穎調節劑及其使用方法
WO2012098256A1 (en) * 2011-01-21 2012-07-26 Université De La Méditerranée Aix - Marseille Ii Anti-cd146 auto-antibodies and uses thereof
DE102011006809A1 (de) * 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
US20140017174A1 (en) * 2011-11-30 2014-01-16 Raja Atreya Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
BR112016010051A2 (pt) 2013-11-04 2017-12-05 Pfizer ?conjugados de anticorpo-fármaco anti-efna4?
RO130965A8 (ro) * 2015-10-16 2017-06-30 Romvac Company S.A. Producerea şi utilizarea oului hiperimun personalizat () în tratamentul psoriazisului
US10792320B2 (en) * 2018-03-28 2020-10-06 Michael Alan Beller Methods for treatment of bladder dysfunction
WO2020176637A1 (en) 2019-02-26 2020-09-03 Pantheryx, Inc. Compositions for management of disorders of the gastrointestinal tract
US11319382B1 (en) 2021-06-28 2022-05-03 King Abdulaziz University Methods for producing and using IgY antibodies targeting the middle east respiratory syndrome coronavirus spike protein to treat or prevent MERS-CoV infection

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014209A1 (en) * 1996-10-02 1998-04-09 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
WO1999036077A1 (en) * 1998-01-19 1999-07-22 Dcv, Inc. Composition and method for treatment and prevention of arthritis and/or autoimmune diseases
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1303869A (zh) * 1999-10-22 2001-07-18 徐永华 鸡蛋黄抗白细胞介素－8抗体、制备方法及其应用
WO2002026256A1 (fr) * 2000-09-28 2002-04-04 Shibayagi Co., Ltd. Inhibiteurs de production excessive d'anticorps, procede de preparation et d'utilisation
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006047298A2 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
WO2006083936A2 (en) * 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3911108A (en) * 1973-02-14 1975-10-07 Diamond Shamrock Corp Process of producing bovine milk products containing specific antibodies
AUPN642795A0 (en) * 1995-11-08 1995-11-30 Northfield Laboratories Pty Ltd Dairy compositions and methods of preparing same
CN1303889A (zh) 1999-12-20 2001-07-18 陶氏康宁东丽硅氧烷株式会社 用于嵌件模塑或双模腔模塑的硅橡胶组合物
KR20040106298A (ko) * 2002-03-21 2004-12-17 아나디스 리미티드 불안정한 생활성 물질 및 포유동물 초유를 포함한 조성물,제조 및 치료 방법
CN1199672C (zh) 2002-04-17 2005-05-04 李永忠 一套预防与治疗癌症中成药
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
JP4264894B2 (ja) * 2004-03-01 2009-05-20 三菱自動車工業株式会社 エアボックス付きグローブボックス
US20090306347A1 (en) 2005-08-29 2009-12-10 Japan Science And Technology Agency Antibody produced using ostrich and method for production thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014209A1 (en) * 1996-10-02 1998-04-09 Ovimmune, Inc. Oral administration of chicken yolk antibodies to treat disease
WO1999036077A1 (en) * 1998-01-19 1999-07-22 Dcv, Inc. Composition and method for treatment and prevention of arthritis and/or autoimmune diseases
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
CN1303869A (zh) * 1999-10-22 2001-07-18 徐永华 鸡蛋黄抗白细胞介素－8抗体、制备方法及其应用
WO2002026256A1 (fr) * 2000-09-28 2002-04-04 Shibayagi Co., Ltd. Inhibiteurs de production excessive d'anticorps, procede de preparation et d'utilisation
CN1377894A (zh) * 2002-04-23 2002-11-06 郭占军 蛋黄抗癌抗体制备方法及其应用
WO2005090406A2 (en) * 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
WO2006047298A2 (en) * 2004-10-21 2006-05-04 The Penn State Research Foundation Eph receptor tumor biomarkers
WO2006083936A2 (en) * 2005-01-31 2006-08-10 Genentech, Inc. Anti-ephb2 antibodies and methods using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
D10. Mao W, et al, Cancer Res. 2004 Feb 1;64(3):781-8 *

Also Published As

Publication number Publication date
US8834872B2 (en) 2014-09-16
NZ575918A (en) 2012-03-30
US20100297140A1 (en) 2010-11-25
US20130295109A1 (en) 2013-11-07
CN101626784B (zh) 2013-07-17
AU2007291891A1 (en) 2008-03-06
EP2061510B1 (en) 2016-06-22
DK2061510T3 (en) 2016-09-05
EP2061510A1 (en) 2009-05-27
EP2061510A4 (en) 2011-01-05
WO2008025099A1 (en) 2008-03-06
CN101626784A (zh) 2010-01-13
JP2010501596A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
US8834872B2 (en) Uses of antibodies
JP7342701B2 (ja) 癌の治療及び／又は予防用医薬組成物
JP6359492B2 (ja) 抗ＩＬ−１α抗体による癌の処置方法
JP2023085465A (ja) 抗ｔｒｏｐ２抗体－薬物コンジュゲート
TW201622743A (zh) 免疫原醣肽、包含該醣肽之組合物及其用途
US20120266264A1 (en) Monoclonal antibodies against gonadotropin-releasing hormone receptor
TW201815423A (zh) 免疫性／治療性聚醣組合物及其用途
JP2009024014A (ja) 癌に対する抗体
TWI843105B (zh) 抗her2 抗體藥物偶聯物在治療尿路上皮癌中的用途
JP2005508839A (ja) ペプチドおよびｍｕｃ１タンパク質に対する抗体
JP2022512709A (ja) 炎症性疾患及び自己免疫疾患を処置する組成物及び方法
JP2023553773A (ja) 抗ｈｍｍｗ抗体、それを含む組成物、及びそれをコードする核酸分子、並びにその使用
JP2022046576A (ja) 炎症性障害の治療療法
CN116059392B (zh) 配体偶联物及其应用
TWI862564B (zh) 癌治療用醫藥
CN114225025A (zh) 含有益生菌的制剂在治疗肠胃疾病中的应用
CN114225024B (zh) 一种用于治疗疾病的益生菌药物
KR101471253B1 (ko) 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
WO2019045025A1 (ja) ワクチン組成物
CN120795151A (zh) 抗犬pd-l1单克隆抗体及其在制备抗癌药物方面的应用
JP2011026252A (ja) 上皮成長因子受容体に対する卵黄抗体およびその用途
JPH09278668A (ja) Ｈｓｐ２７ファミリーに属するタンパク質の麦芽抽出物含有合成抑制剤
CN121002061A (zh) 抗cith3抗体及其用途
CN120018858A (zh) 恶性肿瘤的诊断、预后和治疗
WO2020256110A1 (ja) タイトジャンクション形成誘導剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired